SCHEMBL16930801

SCHEMBL16930801

Cc1ccc(C(N)=NC=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ POLB P06746 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ ALDH1A1 P00352 6/20 0.43
▸ HTT P42858 3/20 0.43
▸ LMNA P02545 3/20 0.43
▸ PKM P14618 3/20 0.43
▸ ATM Q13315 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NLRP1 Q9C000 1/20 0.43
▸ NTSR1 P30989 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ CES2 O00748 1/20 0.43
▸ CES1 P23141 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16930799 0.79 TNF (0.50) HIF1APOLBMAPTALDH1A1HTT
SCHEMBL16930816 0.77 MAPT (0.55) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL16930780 0.76 GRIN2B (0.51) SMN1; SMN2MAPTATMMEN1KMT2A
SCHEMBL16930804 0.76 PRSS1 (0.48) MAPTHPGDRAB9AL3MBTL1NPC1
SCHEMBL16930783 0.75 KDM1A (0.30) —
SCHEMBL16930794 0.75 PARP15 (0.46) POLBMAPTALDH1A1MEN1KMT2A
SCHEMBL16930819 0.73 TSHR (0.56) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL16930824 0.73 MEN1 (0.48) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL10173256 0.73 CYP2D6 (0.55) CYP2D6HIF1ASMN1; SMN2POLBMAPT
SCHEMBL102214 0.73 CYP2D6 (0.55) CYP2D6HIF1ASMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9716235-B2 9,10-bis[2-(p-substituted phenyl)pyrimidin-4-yl] anthracene compounds, methods of preparing the same, organic electroluminescent devices and organic electroluminescent display apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2017-07-25 — — US disclosed
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus BOE TECHNOLOGY GROUP CO., LTD. (CN) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150214487-A1 9,10-Bis[2-(p-substituted phenyl)pyrimidin-4-yl] Anthracene Compounds, Methods of Preparing the Same, Organic Electroluminescent Devices and Organic Electroluminescent Display Apparatus P2RY10, P2RY4, APRT CYP2D6 1601/4885HIF1A 4794/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback